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47* Newborn screening for cystic ﬁbrosis in the eastern part of
Saxonia
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2Screening Laboratory, Technical University of Dresden, Dresden, Germany
Since June 1996 a two step IRT/DNA-screening for cystic ﬁbrosis is performed
at the university screening-laboratory in Dresden in cooperation with the cystic
ﬁbrosis centre at the university children’s hospital. The CF-screening is processed
together with the conventional newborn screening, the participation is voluntary.
After IRT-measurement in case of results over the 99. percentile (60 ng/ml) we look
for the three mutations delta F508, G551 and R553x. In case of IRT >150 ng/ml
or proof of one ore more mutations, the families are referred to the cystic ﬁbrosis
centre for sweat testing, further information and diagnostics.
From June 1st, 1996 to December 31st, 2007 we screened 160 675 newborns, In
1925 cases IRT-results had to be checked, in 142 cases we found CFTR-Mutations
in the second step of the screening.
Over this time we detected 38 patients with cystic ﬁbrosis, which leads to an
incidence of 1:4228 screened newborns.
In three cases newborn screening failed. One was a child with meconium ileus.
One had prenatal diagnostics because of positive family history, where a compound
heterozygote status with a rare second mutation was found, which causes only very
mild disease. The third patient was a premature infant, born in the 31st week of
pregnancy and newborn screening was only performed on the ﬁrst day of life, which
was a failure in performance.
In three patients the screening was conspicuous but sweat test was negative in the
ﬁrst step the diagnosis was delayed.
In conclusion the CF-newborn screening done in Dresden has a sensitivity of
97.22% and a speciﬁty of 99.93%, although we only search for three mutations.
48* First year of Polish National CF Newborn Screening
D.A. Sands1, K. Zybert1, M. Oltarzewski2, A. Sobczynska-Tomaszewska3,
K. Czerska3, A. Norek3, R. Piotrowski1, A. Milanowski1. 1Pediatrics, Institute of
Mother and Child, Warsaw, Poland; 2Screening Department, Institute of Mother
and Child, Warsaw, Poland; 3Genetics, Institute of Mother and Child, Warsaw,
Poland
CF routine national newborn screening in Poland started in September 2006.
Initially newborns from 4 regions were screened (over 124 000), the program
is spreading throughout Poland. The existing screening infrastructure and spare
blood spots after screening for PKU and hypothyreosis are being used. The
program uses a two stage procedure IRT/DNA (covering the 15 most common
mutations in Poland). Final diagnosis is based on CFTR mutation analysis and sweat
test (conventional pilocarpine-iontophoresis and conductometric Nanoduct). Infants
with positive screening results are called to CF centres for veriﬁcation. The same
day both sweat tests are performed. Parents of diagnosed children are informed
about CF, physiotherapy and dietary education. Psychologists are available for
consultation. Genetic counseling is offered. Anthropometric measurements, sputum
bacteriology and tests for elastase-1 in stools are performed. Although F508del
is the most common mutation in the Polish population, to date only 4 infants
are F508del homozygotes. There have been 7 heterozygotes and 5 with different
mutations. We have found elastase-1 very useful in assessing pancreatic function
(single sample of stool) as well as Nanoduct test (immediate result). Half of the
diagnosed group is still pancreatic sufﬁcient. Only 2 have had respiratory symptoms
but radiological changes are detectable in 11 infants. The most common pathogen
has been Staphylococcus aureus. Neonatal screening enables earlier diagnosis (6
weeks) and the introduction of complex therapy in comparison with symptomatic
screening (mean 42 months, median 12 months).
Supported by: Polish Ministry of Health.
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Objectives: Previous studies of Newborn screening programs (NSP) for CF have
shown that early treatment results in improved clinical outcomes increasing the life
span and the quality of life of the patients. In addition parents’ knowledge about
the genetic risks before next pregnancy helps to reduce the born of other children
with CF.
Methods: In Russia since June until December 2006 the pilot study of NSP for
CF was organized. Later since January 2007 NSP has become a National one. The
NSP in Russia is based on Immunoreactive trypsin (IRT) assay from dried blood
spots, followed by IRT retest if ﬁrst one is positive (>70mg/ml), followed by sweat
test if retest is positive (>40mg/ml). If the result of the sweat test is a border-line
the DNA test for the 23 most widespread mutations of CF in Russia is done.
Results: The preliminary results (June 2006–December 29th 2007): 1,965,320
newborns were screened and 185 of them were diagnosed as having CF. Incidence
is 1:10,623. In reality it is even higher. Not all the parents come with their children
for the sweat test because of different reasons.
Thus in 2007 in Moscow 110 613 newborns were screened and 810 had increased
IRT. Repeated test was positive in 107. Sweat test was done in 80 (75%), and CF
was conﬁrmed in 15 cases. The other 27 families didn’t come. Incidence of CF
was 1:7374.
Conclusion: Since January 2007 the CF NSP is performed all over Russia. We
conclude that the incidence of CF in Russia is higher than we have thought before.
Unfortunately we still miss some data mostly because of the lack of information
for parents across Russia about CF Newborn screening program.
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Cystic ﬁbrosis newborn screening (CF NBS) was implemented in France, with a
national strategy in 2002. Diagnosing CF among older siblings (OS) may represent
an additional beneﬁt for NBS; it has not been yet evaluated in literature.
Aim: To report CF care centre’s instruction for sweat testing (ST), and to identify
new CF cases in OS.
Patients and Methods: Centralized data at AFDPHE enabled to have the complete
list of CF affected newborns referred at CF care centres (2005–2006). A question-
naire sent to all of them, excluding those which started NBS before 2002, focused
on the attitude for ST in OS issued from the CF infant’s parents (a) systematically;
(b) if not previously screened; (c) if clinically symptomatic; (d) never. Data were
collected in families with OS (a) number of OS; (b) CF already diagnosed; (c) newly
CF diagnosis (age, ST values and symptoms).
Results: 27 CF care centres answered (96%). For OS, 48% performed ST systemat-
ically, 36% only if not previously screened and 20% only if clinically relevant. Data
were completed for 91% families of the 596 CF NBS infants; a ST was performed
in 71% of the 300 OS (214 families). A CF diagnosis was already known in
18 OS, in addition 17 newly CF cases were detected in 16 families at a median
age of 60 months [30−80], 65% presented more than one symptom [respiratory
(53%), digestive (35%), hypotrophy (18%), ETN (18%)], median chloride value
was 100meq/L [71–108]. 33 alleles were identiﬁed and 6 patients had one mild
mutation (R117H; n = 4, 3 were asymptomatic, chloride levels: 102, 94, 52, and 48).
Conclusion: In families with OS of a CF infant diagnosed via NBS, new CF cases
were diagnosed in 8%. We emphasize the importance of ST even if OS are clinically
asymptomatic (35%).
